Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Launches FosaMax Plus In China; More Launches For Diabetes And Cardiovascular Drugs Expected

This article was originally published in PharmAsia News

Executive Summary

Following Eli Lilly’s launch of Forteo in China last November, Merck is launching FosaMax Plus, a vitamin D compounded version of its osteoporosis blockbuster FosaMax.

You may also be interested in...



Waiting For Blockbusters: Osteoporosis Market Burdened With Black Box Warnings, Reimbursement Woes, And Spare Pipelines

Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity

With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.

Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 1 of 2)

When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC080610

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel